<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Virol</journal-id><journal-id journal-id-type="iso-abbrev">J. Virol</journal-id><journal-id journal-id-type="hwp">jvi</journal-id><journal-id journal-id-type="pmc">jvi</journal-id><journal-id journal-id-type="publisher-id">JVI</journal-id><journal-title-group><journal-title>Journal of Virology</journal-title></journal-title-group><issn pub-type="ppub">0022-538X</issn><issn pub-type="epub">1098-5514</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6384060</article-id><article-id pub-id-type="publisher-id">01548-18</article-id><article-id pub-id-type="doi">10.1128/JVI.01548-18</article-id><article-categories><subj-group subj-group-type="heading"><subject>Vaccines and Antiviral Agents</subject></subj-group><subj-group subj-group-type="editorial-class"><subject>Spotlight</subject></subj-group></article-categories><title-group><article-title>Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease</article-title><alt-title alt-title-type="running-head">Horse F(ab&#x02032;)<sub>2</sub> Protects Monkeys from EVD</alt-title><alt-title alt-title-type="short-authors">Wang et al.</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Hualei</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wong</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhu</surname><given-names>Wenjun</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>He</surname><given-names>Shihua</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Yongkun</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Yan</surname><given-names>Feihu</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Rahim</surname><given-names>Md Niaz</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Bi</surname><given-names>Yuhai</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Zhang</surname><given-names>Zirui</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Cheng</surname><given-names>Keding</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Jin</surname><given-names>Hongli</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Cao</surname><given-names>Zengguo</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Zheng</surname><given-names>Xuexing</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Gai</surname><given-names>Weiwei</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Bai</surname><given-names>Jieying</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Chen</surname><given-names>Weijin</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Zou</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author" equal-contrib="no"><name><surname>Gao</surname><given-names>Yuwei</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Gao</surname><given-names>George F.</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Songtao</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Xia</surname><given-names>Xianzhu</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Qiu</surname><given-names>Xiangguo</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><aff id="aff1"><label>a</label><addr-line>Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, China</addr-line></aff><aff id="aff2"><label>b</label><addr-line>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada</addr-line></aff><aff id="aff3"><label>c</label><addr-line>Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China</addr-line></aff><aff id="aff4"><label>d</label><addr-line>D&#x000e9;partement de Microbiologie-Infectiologie et d&#x02019;Immunologie, Universit&#x000e9; Laval, Qu&#x000e9;bec, Quebec, Canada</addr-line></aff><aff id="aff5"><label>e</label><addr-line>Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada</addr-line></aff><aff id="aff6"><label>f</label><addr-line>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China</addr-line></aff><aff id="aff7"><label>g</label><addr-line>Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou University, Yangzhou, China</addr-line></aff><aff id="aff8"><label>h</label><addr-line>Changchun Institute of Biological Products Co. Ltd., Changchun, China</addr-line></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Schultz-Cherry</surname><given-names>Stacey</given-names></name><role>Editor</role><aff>St. Jude Children's Research Hospital</aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Xianzhu Xia, <email>xiaxzh@cae.cn</email>, or Xiangguo Qiu, <email>xiangguo.qiu@canada.ca</email>.</corresp><fn fn-type="equal"><p>H. Wang, G. Wong, W. Zhu, S. He, and Y. Zhao contributed equally to this article. G. F. Gao, S. Yang, X. Xia, and X. Qiu are co-senior authors.</p></fn><fn fn-type="other"><p><bold>Citation</bold> Wang H, Wong G, Zhu W, He S, Zhao Y, Yan F, Rahim MN, Bi Y, Zhang Z, Cheng K, Jin H, Cao Z, Zheng X, Gai W, Bai J, Chen W, Zou Y, Gao Y, Gao GF, Yang S, Xia X, Qiu X. 2019. Equine-origin immunoglobulin fragments protect nonhuman primates from Ebola virus disease. J Virol 93:e01548-18. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.01548-18">https://doi.org/10.1128/JVI.01548-18</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>12</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="collection"><day>1</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>2</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>93</volume><issue>5</issue><elocation-id>e01548-18</elocation-id><history><date date-type="received"><day>5</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; Crown copyright 2019.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Crown</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="JVI.01548-18.pdf"/><abstract abstract-type="precis"><p>EBOV is one of the deadliest viruses to humans. It has been over 40&#x02009;years since EBOV was first reported, but no cure is available. Research breakthroughs over the past 5&#x02009;years have shown that MAbs constitute an effective therapy for EBOV infections. However, MAbs are expensive and difficult to produce in large amounts and therefore may only play a limited role during an epidemic. A cheaper alternative is required, especially since EBOV is endemic in several third world countries with limited medical resources. Here, we used a standard protocol to produce large amounts of antiserum F(ab&#x02032;)<sub>2</sub> fragments from horses vaccinated with an EBOV vaccine, and we tested the protectiveness in monkeys. We showed that F(ab&#x02032;)<sub>2</sub> was effective in 100% of monkeys even after the animals were visibly ill with EBOV disease. Thus, F(ab&#x02032;)<sub>2</sub> could be a very good option for large-scale treatments of patients and should be advanced to clinical testing.</p></abstract><abstract><title>ABSTRACT</title><p>Ebola virus (EBOV) infections result in aggressive hemorrhagic fever in humans, with fatality rates reaching 90% and with no licensed specific therapeutics to treat ill patients. Advances over the past 5&#x02009;years have firmly established monoclonal antibody (MAb)-based products as the most promising therapeutics for treating EBOV infections, but production is costly and quantities are limited; therefore, MAbs are not the best candidates for mass use in the case of an epidemic. To address this need, we generated EBOV-specific polyclonal F(ab&#x02032;)<sub>2</sub> fragments from horses hyperimmunized with an EBOV vaccine. The F(ab&#x02032;)<sub>2</sub> was found to potently neutralize West African and Central African EBOV <italic>in vitro</italic>. Treatment of nonhuman primates (NHPs) with seven doses of 100&#x02009;mg/kg F(ab&#x02032;)<sub>2</sub> beginning 3 or 5&#x02009;days postinfection (dpi) resulted in a 100% survival rate. Notably, NHPs for which treatment was initiated at 5&#x02009;dpi were already highly viremic, with observable signs of EBOV disease, which demonstrated that F(ab&#x02032;)<sub>2</sub> was still effective as a therapeutic agent even in symptomatic subjects. These results show that F(ab&#x02032;)<sub>2</sub> should be advanced for clinical testing in preparation for future EBOV outbreaks and epidemics.</p><p><bold>IMPORTANCE</bold> EBOV is one of the deadliest viruses to humans. It has been over 40&#x02009;years since EBOV was first reported, but no cure is available. Research breakthroughs over the past 5&#x02009;years have shown that MAbs constitute an effective therapy for EBOV infections. However, MAbs are expensive and difficult to produce in large amounts and therefore may only play a limited role during an epidemic. A cheaper alternative is required, especially since EBOV is endemic in several third world countries with limited medical resources. Here, we used a standard protocol to produce large amounts of antiserum F(ab&#x02032;)<sub>2</sub> fragments from horses vaccinated with an EBOV vaccine, and we tested the protectiveness in monkeys. We showed that F(ab&#x02032;)<sub>2</sub> was effective in 100% of monkeys even after the animals were visibly ill with EBOV disease. Thus, F(ab&#x02032;)<sub>2</sub> could be a very good option for large-scale treatments of patients and should be advanced to clinical testing.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>Ebola virus</kwd><kwd>equine</kwd><kwd>immunoglobulin fragments</kwd><kwd>immunotherapy</kwd><kwd>nonhuman primates</kwd></kwd-group><funding-group><award-group id="award1"><funding-source><institution-wrap><institution>National Science and Technology Major Project of the Ministry of Science and Technology of China</institution></institution-wrap></funding-source><award-id>2015ZX09102025</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Songtao</given-names></name></principal-award-recipient></award-group><award-group id="award2"><funding-source><institution-wrap><institution>National Science and Technology Major Project of the Ministru of Science and Technology of China</institution></institution-wrap></funding-source><award-id>2015ZX09102024</award-id><principal-award-recipient><name><surname>Xia</surname><given-names>Xianzhu</given-names></name></principal-award-recipient></award-group><award-group id="award3"><funding-source><institution-wrap><institution>National Science and Technology Major Project of the Ministry of Science and Technology of China</institution></institution-wrap></funding-source><award-id>2016ZX10004222</award-id><principal-award-recipient><name><surname>Gao</surname><given-names>George Fu</given-names></name></principal-award-recipient></award-group><award-group id="award4"><funding-source><institution-wrap><institution>National Natural Science Foundation of China Cooperation and Exchange Program</institution></institution-wrap></funding-source><award-id>816110193</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Gary</given-names></name></principal-award-recipient></award-group><award-group id="award5"><funding-source><institution-wrap><institution>NSFC Innovative Research Group</institution></institution-wrap></funding-source><award-id>81621091</award-id><principal-award-recipient><name><surname>Gao</surname><given-names>George Fu</given-names></name></principal-award-recipient></award-group><award-group id="award6"><funding-source><institution-wrap><institution>HHS | National Institutes of Health (NIH)</institution><institution-id>https://doi.org/10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>U19AI109762-1</award-id><principal-award-recipient><name><surname>Qiu</surname><given-names>Xiangguo</given-names></name></principal-award-recipient></award-group><award-group id="award7"><funding-source><institution-wrap><institution>Youth Innovation Promotion Association of the Chinese Academy of Sciences (Youth Innovation Promotion Association CAS)</institution><institution-id>https://doi.org/10.13039/501100004739</institution-id></institution-wrap></funding-source><award-id>2017122</award-id><principal-award-recipient><name><surname>Bi</surname><given-names>Yuhai</given-names></name></principal-award-recipient></award-group><award-group id="award8"><funding-source><institution-wrap><institution>Public Health Agency of Canada (PHAC)</institution><institution-id>https://doi.org/10.13039/100011094</institution-id></institution-wrap></funding-source><award-id>IER-143487</award-id><principal-award-recipient><name><surname>Qiu</surname><given-names>Xiangguo</given-names></name></principal-award-recipient></award-group></funding-group><counts><fig-count count="9"/><table-count count="0"/><equation-count count="0"/><ref-count count="29"/><page-count count="10"/><word-count count="4957"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>First reported in 1976, Ebola virus (EBOV) infections in humans result in case fatality rates of up to 90%, with no approved medical countermeasures (<xref rid="B1" ref-type="bibr">1</xref>). Humans infected with EBOV initially present nonspecific, flu-like symptoms, including a sudden onset of fever, headaches, muscle and joint pain, and general fatigue and malaise (<xref rid="B2" ref-type="bibr">2</xref>), before progressing to gastrointestinal, respiratory, vascular, and neurological disease (<xref rid="B1" ref-type="bibr">1</xref>). A maculopapular rash accompanied by hemorrhagic symptoms may be observed in a proportion of patients (<xref rid="B1" ref-type="bibr">1</xref>). Terminal EBOV disease (EVD) is characterized by severe metabolic imbalances, anuria, convulsions, and hypovolemic shock, with death typically due to multiorgan failure and capillary extravasation from vascular permeability and diffuse coagulopathy (<xref rid="B2" ref-type="bibr">2</xref>). Recovery in survivors is slow, and neurological symptoms have been reported (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Historically, EVD outbreaks tend to be sporadic, unpredictable, and localized to isolated regions of sub-Saharan Africa, with fatalities numbering in the hundreds at most (<xref rid="B4" ref-type="bibr">4</xref>). However, an EVD epidemic spread throughout Guinea, Sierra Leone, and Liberia in 2014 to 2016, killing over 11,000 people (<xref rid="B5" ref-type="bibr">5</xref>). Two years later, back-to-back EVD outbreaks in the Equateur and North Kivu provinces in the western and eastern regions, respectively, of the Democratic Republic of the Congo has put EBOV back in the spotlight. In particular, the outbreak in North Kivu is proving to be very challenging to control, due to the volatile security situation (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>EBOV-specific antibody levels are known to correlate statistically with survival from EVD (<xref rid="B7" ref-type="bibr">7</xref>). Monoclonal antibody (MAb)-based candidates, such as ZMAb (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>), ZMapp (<xref rid="B10" ref-type="bibr">10</xref>), and MIL-77 (<xref rid="B11" ref-type="bibr">11</xref>), are promising treatments (<xref rid="B12" ref-type="bibr">12</xref><xref ref-type="bibr" rid="B13">&#x02013;</xref><xref rid="B14" ref-type="bibr">14</xref>), due to successes in the treatment and reversion of advanced EVD in humans and nonhuman primates (NHPs). In addition, ZMapp appears to have a beneficial effect on survival rates in clinical trials (<xref rid="B15" ref-type="bibr">15</xref>). However, MAb-based products can be expensive and time-consuming to manufacture in large quantities, thus restricting their usefulness in areas with limited resources. Polyclonal antisera containing EBOV-specific human IgG produced from transchromosomic cattle have been shown to be efficacious in NHPs when given at 3&#x02009;days postinfection (dpi) (<xref rid="B16" ref-type="bibr">16</xref>), but the cows are transgenic and may not be widely available to researchers in developing countries if they wish to produce their own antibody-based products. An alternate option is passive immunotherapy with polyclonal immunoglobulin F(ab&#x02032;)<sub>2</sub> fragments produced from hyperimmunized horses. Advantages include high yields of antisera (120 to 250&#x02009;g per horse [<xref rid="B17" ref-type="bibr">17</xref>]) in relatively short times, cost efficiency, low risk of contamination by adventitious agents, and standardized production procedures. F(ab&#x02032;)<sub>2</sub> fragments are still commonly used in African, Asian, and Latin American countries to treat envenomation via animal bites and/or stings and rabies (<xref rid="B18" ref-type="bibr">18</xref>) and <named-content content-type="genus-species">Clostridium tetani</named-content> (<xref rid="B19" ref-type="bibr">19</xref>) infections. Additionally, we previously showed that F(ab&#x02032;)<sub>2</sub> derived from horses hyperimmunized with a virus-like particle EBOV vaccine completely protected mice and guinea pigs <italic>in vivo</italic> when treatment was initiated 24 h after challenge (<xref rid="B17" ref-type="bibr">17</xref>). Our aim in this study was to characterize the protective efficacy of equine F(ab&#x02032;)<sub>2</sub> in NHPs.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2.1"><title><italic>In vitro</italic> neutralization properties of F(ab&#x02032;)<sub>2</sub> against EBOV.</title><p>We first tested the <italic>in vitro</italic> neutralizing activities of our current F(ab&#x02032;)<sub>2</sub> batch (which had been stored at 4&#x000b0;C for 33&#x02009;months) against a recombinant, live, Central African (EBOV-Mayinga) (<xref rid="B20" ref-type="bibr">20</xref>) or West African (EBOV-Makona-C07) (<xref rid="B21" ref-type="bibr">21</xref>) EBOV strain expressing enhanced green fluorescent protein (eGFP). F(ab&#x02032;)<sub>2</sub> was found to be potently neutralizing against both tested viruses, with 50% effective concentration (EC<sub>50</sub>) values of 1.7 and 1.4&#x02009;&#x003bc;g/ml against EBOV-Mayinga-eGFP and EBOV-Makona-C07-eGFP, respectively (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The 90% effective concentration (EC<sub>90</sub>) values were 3.2 and 3.7&#x02009;&#x003bc;g/ml against EBOV-Mayinga-eGFP and EBOV-Makona-C07-eGFP, respectively (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><fig id="F1" orientation="portrait" position="float"><label>FIG 1</label><caption><p><italic>In vitro</italic> neutralizing activities of equine F(ab&#x02032;)<sub>2</sub> against EBOV-Mayinga-eGFP and Makona-C07-eGFP in VeroE6 cells. Neutralizing activities of F(ab&#x02032;)<sub>2</sub> against EBOV-Mayinga-eGFP or EBOV-C07-eGFP were compared over different F(ab&#x02032;)<sub>2</sub> concentrations (<italic>x</italic> axis). Fluorescence (<italic>y</italic> axis) from infected VeroE6 cells at 3&#x02009;dpi is shown as a percentage of the fluorescence observed with the PBS control (set at 100%). Dashed lines indicate 50% or 90% inhibition of fluorescence and the associated F(ab&#x02032;)<sub>2</sub> concentrations.</p></caption><graphic xlink:href="JVI.01548-18-f0001"/></fig></sec><sec id="s2.2"><title>Efficacy of F(ab&#x02032;)<sub>2</sub> at 3 dpi against EBOV in NHPs.</title><p>Administration of F(ab&#x02032;)<sub>2</sub> resulted in 100% protection (<xref ref-type="fig" rid="F2">Fig. 2A</xref>), and the F(ab&#x02032;)<sub>2</sub>-treated NHPs did not lose substantial amounts of body weight during the experiment (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). Fever was observed at 4 to 7&#x02009;dpi in all animals, but temperatures returned to baseline by 8&#x02009;dpi (<xref ref-type="fig" rid="F2">Fig. 2C</xref>), and F(ab&#x02032;)<sub>2</sub>-treated NHPs showed virtually no observable signs of disease throughout the course of the experiment (<xref ref-type="fig" rid="F2">Fig. 2D</xref>). In contrast, control animals died at 7 or 8&#x02009;dpi with clinical scores of over 30 and symptoms consistent with EVD. Complete blood count results showed transient decreases in white blood cell (WBC) counts for 2 of 4 F(ab&#x02032;)<sub>2</sub>-treated NHPs (<xref ref-type="fig" rid="F3">Fig. 3A</xref>) but no substantial decreases in lymphocyte (LYM) counts or LYM percentages (<xref ref-type="fig" rid="F3">Fig. 3B</xref> and <xref ref-type="fig" rid="F3">C</xref>). Increases in monocyte (MON) percentages and decreases in neutrophil (NEU) percentages were observed for all F(ab&#x02032;)<sub>2</sub>-treated NHPs (<xref ref-type="fig" rid="F3">Fig. 3D</xref> and <xref ref-type="fig" rid="F3">E</xref>). Changes in platelet (PLT) counts were not observed for any F(ab&#x02032;)<sub>2</sub>-treated NHPs (<xref ref-type="fig" rid="F3">Fig. 3F</xref>). In contrast, control animals showed decreases in WBC counts, MON percentages, and PLT counts, as well as increased NEU percentages, during the course of the experiment.</p><fig id="F2" orientation="portrait" position="float"><label>FIG 2</label><caption><p>Survival rates and clinical findings for NHPs after EBOV challenge at 3&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 3&#x02009;dpi. (A) Survival rates. (B) Percent weight changes. (C) Body temperatures. (D) Clinical scores.</p></caption><graphic xlink:href="JVI.01548-18-f0002"/></fig><fig id="F3" orientation="portrait" position="float"><label>FIG 3</label><caption><p>Hematology and serum biochemistry findings for NHPs after EBOV challenge at 3&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 3&#x02009;dpi. (A) WBC counts. (B) LYM counts. (C) LYM percentages. (D) MON percentages. (E) NEU percentages. (F) PLT counts. (G) ALT levels. (H) ALP levels. (I) AMY levels. (J) TBIL levels. (K) BUN levels. (L) GLU levels.</p></caption><graphic xlink:href="JVI.01548-18-f0003"/></fig><p>Serum biochemistry results showed no substantial changes in the activities or concentrations of alanine aminotransferase (ALT), alkaline phosphatase (ALP), amylase (AMY), total bilirubin (TBIL), blood urea nitrogen (BUN), or glucose (GLU) in the F(ab&#x02032;)<sub>2</sub>-treated NHPs (<xref ref-type="fig" rid="F3">Fig. 3G</xref> to <xref ref-type="fig" rid="F3">L</xref>). In contrast, control animals showed increased ALT, ALP, TBIL, BUN, and GLU levels, as well as decreased AMY levels, which are markers of organ damage and are known to fluctuate with EVD progression. Viremia, as well as shedding via the nasal, oral, and rectal mucosa, was detected by real-time quantitative PCR (RT-qPCR) in both control NHPs (<xref ref-type="fig" rid="F4">Fig. 4A</xref> to <xref ref-type="fig" rid="F4">D</xref>). In contrast, transient viremia and shedding via the oral route were detected for 1 of 4 F(ab&#x02032;)<sub>2</sub>-treated NHPs. When these data were taken together, F(ab&#x02032;)<sub>2</sub> appeared to be effective at postexposure treatment of infected NHPs, and the animals did not become severely ill. Surviving F(ab&#x02032;)<sub>2</sub>-treated animals had detectable levels of circulating serum IgM and IgG after challenge, which were not observed in phosphate-buffered saline (PBS)-treated control animals (<xref ref-type="fig" rid="F5">Fig. 5A</xref> and <xref ref-type="fig" rid="F5">B</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>FIG 4</label><caption><p>Viremia and shedding of NHPs after EBOV challenge at 3&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 3&#x02009;dpi. (A) Blood. (B) Nasal swabs. (C) Oral swabs. (D) Rectal swabs.</p></caption><graphic xlink:href="JVI.01548-18-f0004"/></fig><fig id="F5" orientation="portrait" position="float"><label>FIG 5</label><caption><p>Humoral immunity of NHPs after EBOV challenge at 3&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 3&#x02009;dpi. The amounts of circulating serum antibodies against EBOV were measured by ELISA at the times indicated and expressed as arbitrary units (AU) per milliliter of serum. (A) IgM. (B) IgG.</p></caption><graphic xlink:href="JVI.01548-18-f0005"/></fig></sec><sec id="s2.3"><title>Efficacy of F(ab&#x02032;)<sub>2</sub> at 5 dpi against EBOV in NHPs.</title><p>Results showed that all F(ab&#x02032;)<sub>2</sub>-treated animals survived challenge (<xref ref-type="fig" rid="F6">Fig. 6A</xref>). A loss of body weight was observed for 1 of 3 F(ab&#x02032;)<sub>2</sub>-treated NHPs (<xref ref-type="fig" rid="F6">Fig. 6B</xref>). Fever was observed for all F(ab&#x02032;)<sub>2</sub>-treated animals at 5 to 11&#x02009;dpi but resolved afterwards (<xref ref-type="fig" rid="F6">Fig. 6C</xref>). All F(ab&#x02032;)<sub>2</sub>-treated NHPs were observed to be symptomatic at the beginning of treatment, and symptoms became progressively worse until 8&#x02009;dpi. The animals fully recovered by 28&#x02009;dpi, and no signs of disease were observed (<xref ref-type="fig" rid="F6">Fig. 6D</xref>). In contrast, control animals succumbed to infection by 8&#x02009;dpi, with pronounced weight loss, fever, and increases in clinical scores to &#x0003e;20.</p><fig id="F6" orientation="portrait" position="float"><label>FIG 6</label><caption><p>Survival rates and clinical findings for NHPs after EBOV challenge at 5&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 5&#x02009;dpi. (A) Survival rates. (B) Percent weight changes. (C) Body temperatures. (D) Clinical scores.</p></caption><graphic xlink:href="JVI.01548-18-f0006"/></fig><p>Complete blood count results showed that, by the start of treatment at 5&#x02009;dpi, all F(ab&#x02032;)<sub>2</sub>-treated animals had decreases in WBC counts, LYM counts, and LYM percentages, fluctuating MON percentages and NEU percentages, and substantial decreases in PLT counts (<xref ref-type="fig" rid="F7">Fig. 7A</xref> to <xref ref-type="fig" rid="F7">F</xref>), consistent with EVD. However, increases in all of the aforementioned markers were subsequently observed, suggesting that F(ab&#x02032;)<sub>2</sub> treatment provided the host sufficient time to generate its own immune responses. Control animals showed largely the same trends for these markers but did not recover from the infection. Serum biochemistry results showed that all F(ab&#x02032;)<sub>2</sub>-treated animals had increased ALT, ALP, TBIL, and BUN levels and decreased AMY and GLU levels during the course of the experiment (<xref ref-type="fig" rid="F7">Fig. 7G</xref> to <xref ref-type="fig" rid="F7">L</xref>), suggesting that the animals had suffered organ damage. Control animals again showed the same trends, but the greater magnitude of marker changes indicated that these NHPs had more severe EVD. Analysis of viremia and virus shedding by RT-qPCR showed that the animals had, on average, over 10<sup>6</sup> EBOV genome equivalents (GEQ) per milliliter of blood by the start of F(ab&#x02032;)<sub>2</sub> treatment, but values decreased to undetectable levels by 28&#x02009;dpi (<xref ref-type="fig" rid="F8">Fig. 8A</xref>). Virus shedding via the nasal and oral routes was not observed until 8&#x02009;dpi and reached 10<sup>5</sup> to 10<sup>6</sup> GEQ/ml of sample but resolved by 28&#x02009;dpi (<xref ref-type="fig" rid="F8">Fig. 8B</xref> and <xref ref-type="fig" rid="F8">C</xref>). Shedding via the rectal route was observed at 5&#x02009;dpi and reached 10<sup>4</sup> GEQ/ml of sample but resolved by 28&#x02009;dpi (<xref ref-type="fig" rid="F8">Fig. 8D</xref>). Surviving F(ab&#x02032;)<sub>2</sub>-treated animals had detectable levels of circulating serum IgM and IgG after challenge, which were not observed in PBS-treated control animals (<xref ref-type="fig" rid="F9">Fig. 9A</xref> and <xref ref-type="fig" rid="F9">B</xref>).</p><fig id="F7" orientation="portrait" position="float"><label>FIG 7</label><caption><p>Hematology and serum biochemistry findings for NHPs after EBOV challenge at 5&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 5&#x02009;dpi. (A) WBC counts. (B) LYM counts. (C) LYM percentages. (D) MON percentages. (E) NEU percentages. (F) PLT counts. (G) ALT levels. (H) ALP levels. (I) AMY levels. (J) TBIL levels. (K) BUN levels. (L) GLU levels.</p></caption><graphic xlink:href="JVI.01548-18-f0007"/></fig><fig id="F8" orientation="portrait" position="float"><label>FIG 8</label><caption><p>Viremia and shedding of NHPs after EBOV challenge at 5&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 5&#x02009;dpi. (A) Viremia. (B) Nasal swabs. (C) Oral swabs. (D) Rectal swabs.</p></caption><graphic xlink:href="JVI.01548-18-f0008"/></fig><fig id="F9" orientation="portrait" position="float"><label>FIG 9</label><caption><p>Humoral immunity of NHPs after EBOV challenge at 5&#x02009;dpi. NHPs were given equine F(ab&#x02032;)<sub>2</sub> starting at 5&#x02009;dpi. The amounts of circulating serum antibodies against EBOV were measured by ELISA at the times indicated and expressed as arbitrary units (AU) per milliliter of serum. (A) IgM. (B) IgG.</p></caption><graphic xlink:href="JVI.01548-18-f0009"/></fig></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>In this study, we successfully rescued 100% of EBOV-infected NHPs using an equine F(ab&#x02032;)<sub>2</sub> treatment initiated as late as 5&#x02009;dpi, or 48 to 72 h before death. Passive immunotherapy against EBOV was investigated previously, with mixed results. During the 1995 EVD outbreak in Kikwit, Democratic Republic of the Congo, whole blood from survivors was passively transferred to ill patients, resulting in 7 of 8 survivors (<xref rid="B22" ref-type="bibr">22</xref>). However, a clinical trial in which 99 patients received two consecutive transfusions of 200 to 250&#x02009;ml of convalescent plasma was not associated with a statistically significant improvement in survival rates (<xref rid="B23" ref-type="bibr">23</xref>). It should be noted, however, that levels of EBOV-specific neutralizing antibodies in the convalescent plasma were not tested; therefore, the quality of the plasma was neither standardized nor known.</p><p>Scientists also previously investigated the use of hyperimmune equine antisera against EBOV. This treatment (1&#x02009;mg/kg) was shown to be 100% effective in baboons treated before challenge and 67% effective postexposure, but the challenge dose was low (10 to 30 PFU) (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Delays to viremia and the onset of clinical symptoms were observed, but the treatment (approximately 10&#x02009;mg/kg) did not confer a survival benefit in cynomolgus macaques (<xref rid="B26" ref-type="bibr">26</xref>). However, passive immunotherapy with purified IgG (80&#x02009;mg/kg) from NHPs that survived EVD was successful in conferring postexposure protection when treatment was initiated as late as 2&#x02009;dpi (<xref rid="B27" ref-type="bibr">27</xref>), suggesting that higher doses of antisera are needed. Building on this, our study shows that viral neutralization via F(ab&#x02032;)<sub>2</sub> is sufficient to control EVD and is effective even when animals are symptomatic. However, it is known that immunoglobulin fragments usually have shorter half-lives than IgG and therefore must be administered frequently, as shown in the current study with seven injections. To develop this product further, it will be important to assess whether the half-life of F(ab&#x02032;)<sub>2</sub> can be extended using strategies such as protein conjugation (<xref rid="B28" ref-type="bibr">28</xref>) in order to confer complete protection with fewer treatment doses, lower F(ab&#x02032;)<sub>2</sub> concentrations, and reduced infusion times, as work conditions in EBOV treatment centers in Africa are demanding and multiple infusions can further complicate the work of primary caregivers in the field.</p><p>While the results suggested that F(ab&#x02032;)<sub>2</sub> slowed EBOV infection in NHPs enough that the animals had sufficient time to develop a specific protective response, it is not known whether the animals would survive a rechallenge with EBOV, and this needs to be investigated in the future. A previous study showing complete protection of ZMAb-treated NHPs against an EBOV rechallenge 10&#x02009;weeks after the initial infection suggested that surviving animals might have developed protective immunity. Without directly comparing different treatments under the same challenge conditions, we cannot conclude whether F(ab&#x02032;)<sub>2</sub> is superior or inferior to ZMapp or other antibody-based products. However, our results convincingly show that F(ab&#x02032;)<sub>2</sub> is effective as a postexposure treatment (as late as 5&#x02009;dpi) in NHPs and should be included in clinical trials as soon as possible. Due to well-established production protocols and a good safety record, F(ab&#x02032;)<sub>2</sub> should be considered as an alternative to MAbs for large-scale treatment of patients during EBOV epidemics.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4.1"><title>Ethics statement.</title><p>The experiments were performed in the biosafety level 4 (BSL4) laboratory at the National Microbiology Laboratory in Winnipeg, Canada, under Animal Use Document (AUD) H-16-015. The experiments described in the AUD were approved by the Animal Care Committee (ACC) at the Canadian Science Center for Human and Animal Health and adhered to the national regulations and guidelines outlined by the Canadian Council on Animal Care. To ameliorate suffering, animals were euthanized with an intracardiac injection of pentobarbital sodium if the clinical score reached &#x02265;25 (or &#x02265;20 for control NHPs), following guidelines set by the ACC.</p></sec><sec id="s4.2"><title><italic>In vitro</italic> and <italic>in vivo</italic> study design.</title><p>Neutralization assays were performed <italic>in vitro</italic> using a previously published protocol (<xref rid="B10" ref-type="bibr">10</xref>). Equine F(ab&#x02032;)<sub>2</sub> was generated as described in a previous study (<xref rid="B17" ref-type="bibr">17</xref>), and the same batch was used in this study. In the pilot NHP experiment, rhesus macaques were infected with 1,000 times the 50% tissue culture infectious dose (TCID<sub>50</sub>) of EBOV-Makona-C07. Beginning at 3&#x02009;dpi, animals (<italic>n</italic> = 4) were treated with 100&#x02009;mg/kg of F(ab&#x02032;)<sub>2</sub> once daily until 7&#x02009;dpi (5 doses), with identical doses also being given at 9 and 11&#x02009;dpi. A control animal (<italic>n</italic> = 1) was given identical volumes of PBS in place of F(ab&#x02032;)<sub>2</sub>. Another control animal (<italic>n</italic> = 1) was left untreated. Survival rates, in addition to changes in clinical, hematological, biochemical, and virological parameters, were monitored for 28&#x02009;dpi using previously published protocols (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>To test whether F(ab&#x02032;)<sub>2</sub> was effective later in the course of EVD (when the animals were symptomatic), naive rhesus macaques were first infected with 1,000 TCID<sub>50</sub> of EBOV-Makona-C07. Beginning at 5&#x02009;dpi, animals (<italic>n</italic> = 3) were treated with 100&#x02009;mg/kg of F(ab&#x02032;)<sub>2</sub> once daily until 9&#x02009;dpi (5 doses), with identical doses also being given at 11 and 13&#x02009;dpi. Control animals (<italic>n</italic> = 2) was given identical volumes of PBS in place of F(ab&#x02032;)<sub>2</sub>. All parameters were monitored for 28&#x02009;dpi in a manner similar to that of the pilot experiment.</p></sec><sec id="s4.3"><title>Enzyme-linked immunosorbent assay.</title><p>Enzyme-linked immunosorbent assays (ELISAs) were performed with sera harvested from NHPs, as described previously (<xref rid="B29" ref-type="bibr">29</xref>).</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank Kevin Tierney for his excellent technical assistance in the animal studies.</p><p>This work was supported by the National Science and Technology Major Project of the Ministry of Science and Technology of China (grants 2015ZX09102025, 2015ZX09102024, and 2016ZX10004222), the National Natural Science Foundation of China International Cooperation and Exchange Program (grant 816110193), and the Public Health Agency of Canada, partially supported by grants from the National Institutes of Health (grant U19AI109762-1) and the Canadian Institutes of Health Research (grant IER-143487) to X. Qiu. G. F. Gao is a leading principal investigator of the NSFC Innovative Research Group (grant 81621091). Y. Bi is supported by the Youth Innovation Promotion Association of the Chinese Academy of Sciences (grant 2017122). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</p><p>We declare no conflicts of interest.</p><p>G. F. Gao, S. Yang, X. Xia, and X. Qiu conceived and designed the study, H. Wang, G. Wong, W. Zhu, S. He, Y. Zhao, F. Yan, M. N. Rahim, Y. Bi, Z. Zhang, K. Cheng, H. Jin, Z. Cao, X. Zheng, W. Gai, J. Bai, W. Chen, Y. Zou, Y. Gao, and X. Qiu performed the study, G. Wong, W. Zhu, S. He, and X. Qiu analyzed the data, S. Yang and X. Xia provided the equine F(ab&#x02032;)<sub>2</sub>, and G. Wong and X. Qiu wrote the paper.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sanchez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Geisbert</surname><given-names>TW</given-names></name></person-group>
<year>2013</year>
<source>Filoviridae: Marburg and Ebola viruses</source>. <publisher-name>Lippincott Williams and Wilkins</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nkoghe</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Leroy</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Toung-Mve</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>JP</given-names></name></person-group>
<year>2012</year>
<article-title>Cutaneous manifestations of filovirus infections</article-title>. <source>Int J Dermatol</source>
<volume>51</volume>:<fpage>1037</fpage>&#x02013;<lpage>1043</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-4632.2011.05379.x</pub-id>.<pub-id pub-id-type="pmid">22909355</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Formenty</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sprecher</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>G</given-names></name></person-group>
<year>2016</year>
<article-title>More challenges from Ebola: infection of the central nervous system</article-title>. <source>J Infect Dis</source>
<volume>214</volume>(<issue>Suppl 3</issue>):<fpage>S294</fpage>&#x02013;<lpage>S296</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiw257</pub-id>.<pub-id pub-id-type="pmid">27707893</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="web"><collab>Centers for Disease Control and Prevention</collab>. <year>2018</year>
<article-title>Years of Ebola virus disease outbreaks</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vhf/ebola/history/chronology.html">www.cdc.gov/vhf/ebola/history/chronology.html</ext-link>. <date-in-citation content-type="access-date">Accessed 25 May 2018</date-in-citation>.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="web"><collab>Centers for Disease Control and Prevention</collab>. <year>2017</year>
<article-title>2014&#x02013;2016 Ebola outbreak in West Africa</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html">www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html</ext-link>. <date-in-citation content-type="access-date">Accessed 25 May 2018</date-in-citation>.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maxmen</surname><given-names>A</given-names></name></person-group>
<year>2018</year>
<article-title>War zone complicates roll-out of Ebola vaccine in latest outbreak</article-title>. <source>Nature</source>
<volume>560</volume>:<fpage>289</fpage>&#x02013;<lpage>290</lpage>. <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/articles/d41586-018-05921-4">www.nature.com/articles/d41586-018-05921-4</ext-link>. doi:<pub-id pub-id-type="doi">10.1038/d41586-018-05921-4</pub-id>.<pub-id pub-id-type="pmid">30108347</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Pillet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Alimonti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hogan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Takada</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group>
<year>2012</year>
<article-title>Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates</article-title>. <source>Sci Transl Med</source>
<volume>4</volume>:<fpage>158ra146</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3004582</pub-id>.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Audet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pillet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bello</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cabral</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Strong</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Plummer</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Corbett</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Alimonti</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group>
<year>2012</year>
<article-title>Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies</article-title>. <source>Sci Transl Med</source>
<volume>4</volume>:<fpage>138ra181</fpage>.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name></person-group>
<year>2014</year>
<article-title>Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus</article-title>. <source>Sci Rep</source>
<volume>4</volume>:<fpage>6881</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep06881</pub-id>.<pub-id pub-id-type="pmid">25375093</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Audet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bello</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fernando</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Alimonti</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Fausther-Bovendo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Aviles</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hiatt</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Morton</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Swope</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bohorov</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Bohorova</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pauly</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Velasco</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pettitt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Olinger</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Whaley</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Strong</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Zeitlin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group>
<year>2014</year>
<article-title>Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp</article-title>. <source>Nature</source>
<volume>514</volume>:<fpage>47</fpage>&#x02013;<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature13777</pub-id>.<pub-id pub-id-type="pmid">25171469</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Audet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>M</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fernando</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kroeker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fausther Bovendo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bello</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ippolito</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Saphire</surname><given-names>EO</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Zeitlin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group>
<year>2016</year>
<article-title>Two-mAb cocktail protects macaques against the Makona variant of Ebola virus</article-title>. <source>Sci Transl Med</source>
<volume>8</volume>:<fpage>329ra33</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aad9875</pub-id>.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Olinger</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group>
<year>2014</year>
<article-title>Post-exposure therapy of filovirus infections</article-title>. <source>Trends Microbiol</source>
<volume>22</volume>:<fpage>456</fpage>&#x02013;<lpage>463</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tim.2014.04.002</pub-id>.<pub-id pub-id-type="pmid">24794572</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group>
<year>2015</year>
<article-title>Backs against the wall: novel and existing strategies used during the 2014&#x02013;2015 Ebola virus outbreak</article-title>. <source>Clin Microbiol Rev</source>
<volume>28</volume>:<fpage>593</fpage>&#x02013;<lpage>601</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00014-15</pub-id>.<pub-id pub-id-type="pmid">25972518</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name></person-group>
<year>2015</year>
<article-title>Development of experimental and early investigational drugs for the treatment of Ebola virus infections</article-title>. <source>Expert Opin Investig Drugs</source>
<volume>24</volume>:<fpage>999</fpage>&#x02013;<lpage>1011</lpage>. doi:<pub-id pub-id-type="doi">10.1517/13543784.2015.1052403</pub-id>.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Dodd</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Proschan</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Neaton</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Neuhaus Nordwall</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Koopmeiners</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Beigel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tierney</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lane</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Massaquoi</surname><given-names>MBF</given-names></name>, <name name-style="western"><surname>Sahr</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Malvy</surname><given-names>D</given-names></name></person-group>
<year>2016</year>
<article-title>A randomized, controlled trial of ZMapp for Ebola virus infection</article-title>. <source>N Engl J Med</source>
<volume>375</volume>:<fpage>1448</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">27732819</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luke</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Gerhardt</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Burdette</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Postnikova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Mazur</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Honko</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Oberlander</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Byrum</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ragland</surname><given-names>D</given-names></name>, <name name-style="western"><surname>St Claire</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Janosko</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Glenn</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hooper</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bishop-Lilly</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Frey</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bollinger</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wada</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jiao</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Olinger</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Gunn</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Alter</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Khurana</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hensley</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Jahrling</surname><given-names>PB</given-names></name></person-group>
<year>2018</year>
<article-title>Fully human immunoglobulin G from transchromosomic bovines treats nonhuman primates infected with Ebola virus Makona isolate</article-title>. <source>J Infect Dis</source>
<volume>218</volume>(<issue>Suppl 5</issue>):<fpage>S636</fpage>&#x02013;<lpage>S648</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiy377</pub-id>.<pub-id pub-id-type="pmid">30010950</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gai</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Chi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>X</given-names></name></person-group>
<year>2016</year>
<article-title>Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection</article-title>. <source>Sci Rep</source>
<volume>6</volume>:<fpage>24179</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep24179</pub-id>.<pub-id pub-id-type="pmid">27067649</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><collab>Centers for Disease Control and Prevention</collab>. <year>2010</year>
<article-title>Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies</article-title>. <source>MMWR Recomm Rep</source>
<volume>59</volume>(<issue>RR-2</issue>):<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/mmwr/pdf/rr/rr5902.pdf">www.cdc.gov/mmwr/pdf/rr/rr5902.pdf</ext-link>.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="web"><collab>Centers for Disease Control and Prevention</collab>. <year>2015</year>
<article-title>Tetanus</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html">www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html</ext-link>. <date-in-citation content-type="access-date">Accessed 25 May 2018</date-in-citation>.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><collab>World Health Organization</collab>. <year>1978</year>
<article-title>Ebola haemorrhagic fever in Zaire, 1976: report of an international commission</article-title>. <source>Bull World Health Organ</source>
<volume>56</volume>:<fpage>271</fpage>&#x02013;<lpage>293</lpage>.<pub-id pub-id-type="pmid">307456</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baize</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pannetier</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Oestereich</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rieger</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Koivogui</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Magassouba</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Soropogui</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sow</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Ke&#x000ef;ta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>De Clerck</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tiffany</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dominguez</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Loua</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Traor&#x000e9;</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koli&#x000e9;</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Malano</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Heleze</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bocquin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>M&#x000e9;ly</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Raoul</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Caro</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Cadar</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gabriel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pahlmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tappe</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Schmidt-Chanasit</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Impouma</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Diallo</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Formenty</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Van Herp</surname><given-names>M</given-names></name>, <name name-style="western"><surname>G&#x000fc;nther</surname><given-names>S</given-names></name></person-group>
<year>2014</year>
<article-title>Emergence of Zaire Ebola virus disease in Guinea</article-title>. <source>N Engl J Med</source>
<volume>371</volume>:<fpage>1418</fpage>&#x02013;<lpage>1425</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1404505</pub-id>.<pub-id pub-id-type="pmid">24738640</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mupapa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Massamba</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kibadi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kuvula</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bwaka</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kipasa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Colebunders</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Muyembe-Tamfum</surname><given-names>JJ</given-names></name></person-group>
<year>1999</year>
<article-title>Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients</article-title>. <source>J Infect Dis</source>
<volume>179</volume>(<issue>Suppl 1</issue>):<fpage>S18</fpage>&#x02013;<lpage>S23</lpage>. doi:<pub-id pub-id-type="doi">10.1086/514298</pub-id>.<pub-id pub-id-type="pmid">9988160</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Griensven</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>T</given-names></name>, <name name-style="western"><surname>de Lamballerie</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Semple</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Gallian</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Baize</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Horby</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Raoul</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Magassouba</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Antierens</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lomas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Faye</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Sall</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Fransen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Buyze</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ravinetto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tiberghien</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Claeys</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>De Crop</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lynen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bah</surname><given-names>EI</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Delamou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Weggheleire</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Haba</surname><given-names>N</given-names></name></person-group>
<year>2016</year>
<article-title>Evaluation of convalescent plasma for Ebola virus disease in Guinea</article-title>. <source>N Engl J Med</source>
<volume>374</volume>:<fpage>33</fpage>&#x02013;<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1511812</pub-id>.<pub-id pub-id-type="pmid">26735992</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikha&#x0012d;lov</surname><given-names>VV</given-names></name>, <name name-style="western"><surname>Borisevich</surname><given-names>IV</given-names></name>, <name name-style="western"><surname>Chernikova</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Potryvaeva</surname><given-names>NV</given-names></name>, <name name-style="western"><surname>Krasnianski&#x0012d;</surname><given-names>VP</given-names></name></person-group>
<year>1994</year>
<article-title>The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever</article-title>. <source>Vopr Virusol</source>
<volume>39</volume>:<fpage>82</fpage>&#x02013;<lpage>84</lpage>. (In Russian.)<pub-id pub-id-type="pmid">8017061</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St Claire</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Ragland</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Bollinger</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jahrling</surname><given-names>PB</given-names></name></person-group>
<year>2017</year>
<article-title>Animal models of Ebolavirus infection</article-title>. <source>Comp Med</source>
<volume>67</volume>:<fpage>253</fpage>&#x02013;<lpage>262</lpage>.<pub-id pub-id-type="pmid">28662754</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jahrling</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Geisbert</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Swearengen</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Jaax</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Huggins</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>LeDuc</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>CJ</given-names></name></person-group>
<year>1996</year>
<article-title>Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses</article-title>. <source>Arch Virol Suppl</source>
<volume>11</volume>:<fpage>135</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">8800795</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dye</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Herbert</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Kuehne</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Barth</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Muhammad</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Zak</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Ortiz</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Prugar</surname><given-names>LI</given-names></name>, <name name-style="western"><surname>Pratt</surname><given-names>WD</given-names></name></person-group>
<year>2012</year>
<article-title>Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>109</volume>:<fpage>5034</fpage>&#x02013;<lpage>5039</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1200409109</pub-id>.<pub-id pub-id-type="pmid">22411795</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Compson</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Jairaj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ceska</surname><given-names>T</given-names></name>, <name name-style="western"><surname>West</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zaccheo</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Dave</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lawson</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Humphreys</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Heywood</surname><given-names>S</given-names></name></person-group>
<year>2016</year>
<article-title>Extending the half-life of a Fab fragment through generation of a humanized anti-human serum albumin Fv domain: an investigation into the correlation between affinity and serum half-life</article-title>. <source>MAbs</source>
<volume>8</volume>:<fpage>1336</fpage>&#x02013;<lpage>1346</lpage>. doi:<pub-id pub-id-type="doi">10.1080/19420862.2016.1185581</pub-id>.<pub-id pub-id-type="pmid">27315033</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakayama</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Yokoyama</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Miyamoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Igarashi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kishida</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Matsuno</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Marzi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Saijo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Takada</surname><given-names>A</given-names></name></person-group>
<year>2010</year>
<article-title>Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies</article-title>. <source>Clin Vaccine Immunol</source>
<volume>17</volume>:<fpage>1723</fpage>&#x02013;<lpage>1728</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00170-10</pub-id>.<pub-id pub-id-type="pmid">20861331</pub-id></mixed-citation></ref></ref-list></back></article>